CLINICAL & PIPELINE·Drug Approval
Dr. Falk Pharma GmbH Concludes Pivotal Phase III Trial for Budesonide in Eosinophilic Esophagitis
Dr. Falk Pharma GmbH has completed its pivotal Phase III clinical trial (NCT02493335) for Budesonide Orodispersible Tablets in Eosinophilic Esophagitis. This milestone positions the company for potential regulatory filings, offering a specialized treatment option for adult EoE patients. Procurement directors and regulatory heads should monitor the data release and subsequent market entry, which could reshape treatment paradigms and market access strategies for this chronic condition.
90-Day Activity
Dr. Falk Pharma GmbHBudesonideHSN 2937.22.00
RMRohan Mehta· Senior Supply Chain Intelligence Analyst8d ago